Massachusetts Medical Society, New England Journal of Medicine, 19(372), p. 1791-1800
Yearbook of Cardiology 2016, p. 24-26
Full text: Download
To the Editor: In their report on the PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients with Prior Heart Attack using Ticagrelor Compared to Placebo on the Background of Aspirin-Thrombolysis in Myocardial Infarction 54) trial, Bonaca et al. (May 7 issue)(1) suggest that the benefit of dual antiplatelet therapy comes at a cost of an increased risk of bleeding events. A dual antiplatelet regimen administered at an even lower dose than the one used in this study could confer a reduced risk of bleeding events and improved secondary prophylaxis against recurrent ischemic events as compared with aspirin. We successfully tested . . .